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The aim of this study was to investigate both functionally and structurally bronchodilator effects of 
Pituitary adenylate cyclase activating peptide (PACAP38) and acetyl-[Ala15, Ala20] PACAP38-polyamide, 
a potent PACAP38 analog, in rats challenged by methacholine (MeCh). Male Wistar rats were divided 
randomly into five groups. Groups 1 and 2 inhaled respectively aerosols of saline or increasing doses 
of MeCh (0.5, 1, 2.12, 4.25, 8.5, 17, 34 and 68mg/L). The other groups received terbutaline (Terb)  
(250 µg/rat) (10-6 M), PACAP38 (50 µg/rat) (0.1 mM) or PACAP38 analog (50 µg/rat) associated to 
MeCh from the dose of 4.25 mg/L. Total lung resistances (RL) were recorded before and 2 min after MeCh 
administration by pneumomultitest equipment. MeCh administration induced a significant and a dose-
dependent increase (p<0.05) of RL compared to control rats. Terb, PACAP38 and PACAP38 analog reversed 
significantly the MeCh-induced bronchial constriction, smooth muscle (SM) layer thickness and bronchial 
lumen mucus abundance. PACAP38 analog prevents effectively bronchial smooth muscle layer thickness, 
mucus hypersecretion and lumen decrease. Therefore, it may constitute a potent therapeutic bronchodilator.
Uniterms: Pituitary adenylate cyclase activating peptide/effects/inflammatory lung diseases. Pituitary 
adenylate cyclase/analogs/effects in inflammatory lung diseases. Methacholine. Bronchodilators/effects. 
Inflammatory lung diseases/treatment.
O objetivo deste estudo foi investigar funcionalmente e estruturalmente efeito broncodilatador do peptídeo 
ativador da adenilato ciclase pituitária (PACAP1-38) e da acetil-[Ala15, Ala20]PACAP 38-poliamida, 
potente análogo do PACAP-38, nos ratos desafiados pelo metacolina (MeCh). Ratos Wistar machos foram 
aleatoriamente divididos em cinco grupos. Grupos 1 e 2, inalando aerossóis de solução salina ou doses 
crescentes de MeCh (0,5, 1, 2,12, 4,25, 8,5, 17, 34 e 68 mg/L). Os outros grupos recebendo terbutalina 
(Terb) (250 µg/rato) (10-6M), PACAP-38 (50 µg/rato) (0.1 mM) ou análogo do PACAP-38 (50 µg/rato) 
associados a MeCh na dose de 4,25 mg/L. A resistência pulmonar total (RL) foi registrada antes e 2 min 
após a administração de Mech pelo equipamento pneumomultiteste. A administração MeCh induziu 
aumento significativo e dose dependente (p<0,05) de RL em comparação com ratos do grupo controle. 
Terb e PACAP1-38 e análogo do PACAP-38 reverteram, significativamente, a constrição brônquica 
induzida por Mech, a espessura do músculo liso (SM) e abundância de muco do lume brônquico. O 
análogo PACAP-38 do mesmo modo que a Terb impediu a responsividade brônquica a MeCh e pode se 
constituir em um importante regulador no desenvolvimento da doença inflamatório pulmonar. Contudo, 
o uso do peptídeo nativo para aplicações terapêuticas é limitado por sua baixa estabilidade metabólica. 
Consequentemente, o análogo metabolicamente estável representa ferramenta promissora no tratamento 
de doenças pulmonares inflamatórias.
Unitermos: Adenilato cilase da pituitária/efeitos/doença pulmonar inflamatória. Adenilato cilase 
da pituitária/análogos/efeitos em doença pulmonar inflamatória. Metacolina. Resistência pulmonar. 
Broncodilatores/efeitos. Doenças pulmonares inflamatórias/tratamento.
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INTRODUCTION
Pituitary adenylate cyclase activating peptides 
(PACAPs) are vasoactive intestinal peptide (VIP)-
like neuropeptides that have been purified from ovine 
hypothalami (Miyata et al., 1989). Two endogenous forms 
of PACAP have been identified. PACAP38 and PACAP27 
(the N-terminal residue of PACAP38) are powerful 
stimulants of adenylate cyclase in anterior pituitary cells 
in culture, a feature from which derives the name (Miyata 
et al., 1989; Arimura, 1998). Different forms of PACAP 
and its analogs, known for their bronchodilator properties, 
have been tested for the treatment of obstructive airway 
diseases such as asthma which is characterized by 
bronchial hypereractivity and seems to have increasing 
rates of morbidity and mortality despite progress in 
therapeutic methods (Okazawa et al., 1998; Van Schoor, 
Joos, Pauwels, 2000).
PACAP38 makes up to 80-90 of the total PACAP 
in the body and has longer lasting bronchodilator activity 
on constricted airways than PACAP27. In the guinea-
pigs, PACAP38 inhibits smooth muscle tone induced by 
acetylcholine and histamine and causes more sustained 
inhibition of bronchoconstriction than VIP without 
cardiovascular side effects (Lindén et al., 1995; 1999). 
PACAP38 is present in lung and it constitutes a potent 
endogenous bronchodilator through inhibition of smooth 
muscle contraction induced by cholinergic and excitatory 
non-adrenergic and non cholinergic nerves (Shigyo et al., 
1998; Yoshida et al., 2000).
Different studies were conducted to assess the role 
of PACAPs against pulmonary inflammation (Delgado et 
al., 1999; Vaudry et al., 2009; Elekes et al., 2011; Reglodi 
et al., 2012) and bronchial hyperresponsiveness and 
bronchoconstriction (Saguchi et al., 1997; Kinhult et al., 
2000; Kinhult, Uddman, Cardell, 2001) to various stimuli 
either in vivo or in vitro. However, PACAP38 has not been 
tested against methacholine-induced bronchoconstriction 
on rat lung in vivo. Methacholine (MeCh) is a synthetic 
muscarinic agonist more stable than acetylcholine and 
better-tolerated than histamine and carbachol (Van Schoor, 
Joos, Pauwels, 2000; Sterk et al., 2001; Nair, Hanrahan, 
Hargreave, 2009). On the other hand, as for most natural 
peptides, the clinical use of PACAP38 is limited by its low 
metabolic stability (Bourgault et al., 2008). The half-life of 
PACAP38 in the human blood ranges between 5 and 10 min 
because it is rapidly metabolized by dipeptidyl peptidase IV 
(DPP IV), a ubiquitous peptidase that liberates dipeptides 
from the N-terminus of regulatory peptides (Mentlein, 
1999; Li et al., 2007). As a result, the agonistic activity of 
the peptide is suppressed by the DPP IV-induced cleavage 
since the amino terminal domain of PACAP is essential for 
the activation of PAC-1 receptor and N-terminally truncated 
forms of PACAP behave as antagonists for this receptor 
which is principally responsible for the biological activity 
of PACAP. The Acetyl-[Ala15, Ala20] PACAP38-polyamide, 
a potent PACAP38 analog, has improved plasmatic stability. 
Indeed, this bi-alanine-substituted analog was more stable 
than PACAP38 in isolated human plasma. Moreover, it 
exhibited a complete resistance to DPP IV degradation, 
a high affinity towards the PAC-1 receptor and a potent 
activity associated with this receptor (Bourgault et al., 
2008; Dejda et al., 2011). Consequently, the development 
of modified PACAP analogs with a lower susceptibility 
to protease degradation represented a promising strategy 
to further investigate the physiological roles of PACAP. 
Such stabilized analogs have a potent activity for the PAC-
1 receptor and would also facilitate the assessment of the 
usefulness of PACAP as a drug candidate for the treatment 
of different pulmonary diseases. To our knowledge, there are 
no in vivo studies on bronchodilator effects and muscarinic 
airway responsiveness of this novel PACAP38 analog.
The aim of the current study was to examine the 
bronchodilator effects of inhaled PACAP38 and PACAP38 
analog against MeCh challenge compared to terbutaline 
(Terb), a selective β2-adrenoceptor agonist clinically 
used for the long-term treatment of obstructive airway 
diseases and for the treatment of acute bronchospasm 
effects (Johnson, 2001; Nair, Hanrahan, Hargreave, 2009).
MATERIAL AND METHODS
Animals and chemicals
Male Wistar rats (50 days of age) were purchased 
from the Tunisian Company of Pharmaceutical Industries 
(SIPHAT, Rades, Tunis, Tunisia). The animals were 
housed under controlled conditions of temperature (25 °C) 
and light (12:12 light:dark). All animals were provided 
with food and water ad libitum.
The 38-amino-acid form of PACAP and acetyl-
[Ala15, Ala20] PACAP38-polyamide were synthesized 
using a solid phase strategy combined with the chemistry 
methodology (Bourgault et al., 2008). Methacholine and 
Ketamine were purchased from Sigma (St. Louis, MO, 
USA) and Terbutaline 5mg/2mL solution nebulizer was 
obtained from AstraZneneca laboratory. All the other 
reagents were of the highest purity and were purchased 
from the Sigma Chemical Co. Animals were cared for 
under the Tunisian Code of Practice for the Care and Use 
of Animals for Scientific Purposes. Experimental protocols 
were approved by the Faculty Ethics Committee.
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Experimental design and lung resistance (RL) 
measurement
Animals were anesthetized with ketamine 
(100 mg/kg). The necks were opened, the trachea exposed 
by a mid-line incision and a tracheal cannula was inserted. 
A second balloon-tipped catheter was inserted into the 
lower 1/3 of the oesophagus and connected to a pressure 
transducer to measure the intra-oesophageal pressure. A 
small pneumotachograph (PTG, 8431B, Hnans Rudoplh, 
Kansas, USA) was connected to the tracheal cannula at 
the time of measurement of the flow rate. Period was set at 
10 seconds to avoid change in ventilation due to the PTG 
dead volume. The PTG was connected to two-differential 
pressure transducers. Both transducers were assembled 
together with connecting valves to ease the calibration 
and clearing of the esophageal catheter (Pneumomultitest 
ERMS, Toulouse, France). Total lung resistance (RL) was 
determined using a first order mechanical model of the lung. 
Aerosols were generated through a DeVibliss nebulizer 
(Ref.123016 Marquette Medical products, Englewood Co., 
USA) connected to a compressor (flow rate 100 mL/s) with 
a flow rate of 0.1 mL/min in a rigid plastic chamber placed 
over the rat body (Zhao et al., 2002).
Rats were randomized into five experimental groups 
(n=8) as follows: (1) animals received aerosols of MeCh 
in increasing doses ( 0.5, 1, 2.12, 4.25, 8.5, 17, 34 and 68 
mg/L) within the chamber for 1min with 3min intervals 
between each dose (Zhao et al., 2002), (2) animals were 
challenged by increasing doses of MeCh and received 
terbutaline (Terb) (250 µg/rat) in an aerosol form, (3) 
animals were challenged by increasing doses of MeCh and 
received aerosols of PACAP dissolved in NaCl 0.9% (50 
µg/rat) (Lindén et al., 1999), (4) animals were challenged 
by increasing doses of MeCh and exposed to aerosols of 
PACAP-38 analog dissolved in NaCl 0.9% (50 µg/rat), 
(5) Control rats received aerosols of isotonic saline at the 
same duration and speed of aersolization. For all-treated 
groups, exposure to Terb, PACAP or PACAP analog began 
from the dose of 4.25 mg/mL and the exposure period 
was 1 minute after each MeCh challenge. Total lung 
resistances (RL) were measured before and 2 min after 
each treatment. At the end of the experiment and after the 
last RL measurement, rats were immediately scarified by 
exsanguinations via cardiac puncture followed by a rapid 
decapitation.
Histopathology and morphometry
Immediately after sacrifice, lungs were harvested, 
washed with ice cold saline and fixed overnight at room 
temperature in paraformaldehyde 4% in 0.1 M phosphate 
buffer, pH 7.4. The samples were dehydrated with ethanol 
and toluene series and embedded in paraffin. Serial sections 
(5µm) were mounted on gelatin-coated glass slides, cut and 
stained with hematoxylin and eosin for histopathological 
analysis and using the trichrome Masson’s technique for 
the morphometric study. The quantitative measurements 
were made with a computerized image analysis system 
using Image-Pro Plus version 4.5 software (Media 
Cybernetics Inc, Silver Spring, MD, USA). The protocol 
was systematized into three phases: capture, processing 
and quantification. The images were captured at a size 
of 551/400 pixels at x40, x100 and x200 magnifications. 
All the bronchi found to be smaller than or equal to the 
size of the histological field were captured. With the aim 
of studying only the bronchi cut perpendicularly to their 
longitudinal axis, all the bronchi whose greatest diameter 
was at least twice as large as the least diameter were 
discarded. Airway size defined by the reticular basement 
membrane perimeter (pbm), the total area of the smooth 
muscle layer (ASMarea) and the internal bronchial lumen 
diameter were measured by planimetry according to 
the method of James et al. (2012). The main outcome 
of interest was the ASM thickness which is the ASMarea 
normalized for airway size divided by the pbm (ASMarea /
pbm) and expressed in µm. Thereafter, the airways were 
divided into three categories according to their pbm, as 
described by Sapienza et al. (1991): pbm≤1mm (small), 
pbm>1mm and ≤ 2mm (medium) and pbm>2mm (large). 
The measurements were made using 10 randomly chosen 
medium-sized bronchi per animal (n=8). 
Statistics
Data were analyzed using PRISM software 
(GraphPad Software, San Diego, CA, USA). The results 
were expressed as means±standard deviations of the mean 
(SD). Differences between means were evaluated by one-
way analysis of variance (ANOVA) followed by Tukey’s 
multiple comparison as the post hoc test. All statistical 
tests were two-tailed and a p value of 0.05 or less was 
considered significant.
RESULTS
Lung resistance
Lung resistances (RL) in rats before and after 
exposure to NaCl aerosols were identical (0.41 ± 0.04 vs 
0.49 ± 0.05 KPa/L/s), while MeCh inhalation induced a 
dose-dependent increase of RL indicating that this agent 
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is a potent bronchoconstrictor. A significant increase was 
observed by the dose of 4.25mg/L compared to control 
(0.853 ± 0.15 vs 0.41 ± 0.04 KPa/L/s, p<0.05). With the 
highest dose of MeCh, bronchial resistance reached 1.90 
± 0.20 KPa/L/s. Interestingly, co-exposure to PACAP38 
analog (50µg/rat), PACAP38 (50µg/rat) as well as 
Terb (250 µg/rat) aerosols abolished totally the airway 
hyperresponsiveness for all doses of MeCh (Figure 1).
Lung histopathology
A histological study revealed that in control rats, 
lung sections showed large bronchial lumen with little 
mucus and reduced smooth muscle layer (Figure 2A). 
After MeCh-challenge, pulmonary sections showed 
obstructed bronchial lumen with abundant mucus and 
thick smooth muscle layer (Fig.2.B). Protective effects 
of PACAP38 and Terb were tested in MeCh-challenged 
rats. As shown in Figures 2.C, 2.D and 2.E, co-treatment 
with PACAP38, PACAP38 analog or Terb inhibited 
airway obstruction in MeCh-inhaled rats and prevented 
bronchoconstriction and mucus hypersecretion.
Morphometric analyses
All the morphometric parameters were carried on 
medium-sized airways. The Table I showed a homogeneity 
within the range of bronchi sizes measured by their 
basement membrane parameters (pbm).
Bronchoconstriction was evaluated by measuring 
bronchial lumen diameter. In MeCh-challenged rats, 
bronchial lumen diameter decreased significantly 
compared to control group (64.67 ± 28.86 vs 515.70 ± 
81.03 µm, p<0.05). MeCh effect was abolished by inhaled 
PACAP38, PACAP38 analog or Terb (Figure 3A). MeCh 
treatment resulted also in increased smooth muscle layer 
thickness by about 153 % (48.25 ± 11.26 vs 19.06 ± 
4.20 µm) and co-administration of PACAP38, PACAP38 
analog or Terb prevented this effect (Figure 3B).
DISCUSSION
The present study indicated that inhaled MeCh 
increased in a dose-dependent manner total lung resistance by 
the contraction of airway smooth muscle. Histopathological 
and morphometric observations confirmed this result 
showing an increase of the smooth muscle layer thickness 
and accumulation of mucus leading to the obstruction of 
the bronchial lumen. Previous studies indicated that MeCh 
effect on bronchial smooth muscle cells, endothelial cells 
and mucus-producing cells was mediated by muscarinic 
receptors with an increase in intracellular calcium (Van 
Schoor, Joos, Pauwels, 2000; Anderson, 2010; Svensson, 
Bjermer, Tufvesson, 2014). Interestingly, we showed for 
the first time that PACAP analog as well as PACAP38 and 
Terb potentially reversed airway resistance induced by 
MeCh. This result is supported by data demonstrating the 
presence of PACAP-containing nerve fibers in association 
with bronchial smooth muscle in primates and rodents 
(Uddman et al., 1991; Busto et al., 2000). Moreover, a 
moderate number of vascular smooth muscle and around 
seromucus glands, suggest that this peptide may play a role 
in the endogenous regulation of mucus secretion (Kinhult et 
al., 2000). Bronchial relaxant effect of PACAP is mediated 
through a specific receptor coupled to the adenyl cyclase 
pathway (Laburthe, Couvineau, 2002; Wilson, Cumming, 
2008). Terbutaline a β2-agonist was used as a reference to 
assess the bronchodilator action of PACAP. It stabilized 
the membrane of mast cells and relaxed bronchial smooth 
muscles thus relieving dyspnea of the patient quickly and 
improved the respiration (Xiong et al., 2008).
In the present study, we have showed that PACAP38 
reversed potentially MeCh-induced bronchoconstriction 
and mucus hypersecretion in rats. However, the poor 
metabolic stability of the native peptide limits its 
therapeutic use because it undergoes rapid enzymatic 
degradation after systemic introduction (Zhu et al., 
2003). The Acetyl-[Ala15, Ala20] PACAP38-polyamide, 
a potent stable PACAP38 analog, which exhibits 
complete resistance to DPP IV degradation, increases 
FIGURE 1 - Effect of terbutaline, PACAP38 or PACAP38 analog 
on lung resistances (RL) of rats challenged by metacholine 
(Mech). Each value is the mean ± SD of 8 determinations. * p 
≤ 0.05, ** p ≤ 0.01 compared to control; # p ≤ 0.05, ## p ≤ 0.01 
compared to Terb, PACAP38 or PACAP38 analog challenged 
groups at the corresponding dose (Tukey’s multiple comparison 
post hoc test).
Pituitary Adenylate Cyclase Activating Peptide (1-38) and its analog (Acetyl-[Ala15, Ala20] PACAP 38-polyamide) 685
metabolic activity and behaves as an agonist of the PAC1 
receptor. Our results indicate, for the first time, that the 
PACAP-38 analog produces a significant inhibitory 
effect on muscarinic airway responsiveness in vivo 
after airway administration. Indeed, the Acetyl-[Ala15, 
Ala20] PACAP38-polyamide could have improved 
pharmacokinetic effects compared to the native peptide 
because of its high metabolic stability.
In conclusion, although further investigations are 
needed in rodents and humans to clarify the bronchodilator 
mechanism of PACAP38 analog and to assess its potential 
side effects, the use of such a novel DPP IV-resistant 
analog represented a promising tool for the in vivo 
exploration of the physiological roles of PACAP and for 
FIGURE 2 - Photomicrographs of hematoxylin-eosin-stained lung sections from rats showing the structure of a representative 
bronchus. (A) after inhalation of saline. (B) after Mech challenge: note the bronchoconstriction, the increase of the smooth 
muscle (SM) layer and the abundance of mucus (M) in the bronchial lumen (BL). (C), (D) and (E) after metacholine + terbutaline, 
metacholine + PACAP and metacholine + PACAP38-analog treatment, respectively: note the bronchodilator effect of Terb, PACAP38 
and PACAP38 analog. Magnification: ×400.
TABLE I - Airway sizes of medium-sized bronchi examined for 
morphometry in the different experimental groups
Experimental groups Pbm (mm)
NaCl 1.70±0.11
MeCh 1.75±0.13
MeCh+Terb 1.74±0.11
MeCh+PACAP38 1.74±0.08
MeCh+PACAP38 analog 1.76±0.11
Airway sizes were determined by measuring basement 
membrane diameters (pbm). Values (means ±standard 
deviations, n=10 bronchi per animal (n=8)) are not significantly 
different (Tukey’s multiple comparison post hoc test).
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future pharmacological interventions in the treatment of 
obstructive lung diseases.
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